Clinical Trials on Neuroendocrine Carcinomas in Japan

Total 811 results

Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Genzyme, a Sanofi Company

Completed

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma

Japan
Hoffmann-La Roche

Recruiting

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Small Cell Lung Cancer | Neuroendocrine Carcinoma

United States, Japan, Denmark, Spain, Poland
Novartis Pharmaceuticals
Eckert & Ziegler Radiopharma GmbH

Recruiting

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Neuroendocrine Neoplasms

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
National Cancer Center, Japan
Merck Sharp & Dohme LLC

Recruiting

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas

Japan
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

United States, Spain, Germany, Japan, France
Wakayama Medical University
Osaka University; Kyoto Prefectural University of Medicine; Nara Medical University and other collaborators

Completed

Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy

Pancreatic Cancer | Chronic Pancreatitis | Pancreatic Cystic Lesions | Pancreatic Neuroendocrine Tumors | Pancreatic Pseudocysts

Japan
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Niigata University Medical & Dental Hospital
Merck Sharp & Dohme LLC

Recruiting

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Ovarian Squamous Cell Carcinoma

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

Melanoma

Japan
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Not yet recruiting

A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma (ANNIVERSARY)

Muscle-invasive Urothelial Carcinoma

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

Melanoma

Japan
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Active, not recruiting

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

Japan
Keio University
Merck Sharp & Dohme LLC; Ohara Pharmaceutical Co., Ltd.

Recruiting

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Melanoma

Japan
EMD Serono Research & Development Institute, Inc.

Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Carcinoma, Merkel Cell

United States, Spain, Australia, Italy, Germany, France, Japan
Zeria Pharmaceutical

Completed

Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

Japan
Translational Research Center for Medical Innovation...
Okayama University; Japanese Gynecologic Oncology Group (JGOG)

Recruiting

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | BRCA1 and/or BRCA2 Variant Carriers

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Advanced or Metastatic Renal Cell Carcinoma

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Yamagata University

Unknown

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (CROSS-J-RCC)

Metastatic Renal Cell Carcinoma

Japan
AstraZeneca

Completed

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Carcinoma | Cancer | Tumors

Japan
Kyowa Kirin Co., Ltd.

Completed

A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) (JET-HCC)

Liver Cancer

Japan
Hokkaido University Hospital
Merck Sharp & Dohme LLC

Recruiting

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

Effect of Drug

Japan
Kansai Hepatobiliary Oncology Group

Unknown

P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.

Hepatocellular Carcinoma

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

Japan
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Keio University

Recruiting

Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel

Esophageal Squamous Cell Carcinoma

Japan
National Cancer Center, Japan

Recruiting

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC (ARMADILLO)

Esophageal Squamous Cell Carcinoma

Japan
Pfizer

Completed

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

Carcinoma

Japan
Pfizer

Completed

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors

Japan
Bristol-Myers Squibb

Completed

A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread

Kidney Cancer | Renal Cell Carcinoma

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Southern Tohoku BNCT Research Center

Active, not recruiting

Dose Optimized BNCT for Head and Neck Cancer (ST-BNCT2001)

Head and Neck Cancer | Squamous Cell Carcinoma

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

Renal Cell Carcinoma

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Solid Tumors

Japan
Kindai University

Unknown

Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)

Carcinoma, Hepatocellular | Hepatocellular Carcinoma | Liver Neoplasm | Unresectable Hepatocellular Carcinoma

Japan
Bayer

Completed

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

Carcinoma, Renal Cell

Japan
Merck KGaA, Darmstadt, Germany

Completed

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Carcinoma of the Head and Neck

Japan
Telix International Pty Ltd

Completed

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (ZIRDAC-JP)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Japan
Eisai Co., Ltd.

Completed

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

Japan
Cancer Intelligence Care Systems, Inc.
Stella Pharma Corporation

Completed

Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma

Angiosarcoma | Malignant Melanoma

Japan
Takeda

Active, not recruiting

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Hepatocellular Cancer

Japan
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Takeda

Completed

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Renal Cell Carcinoma

Japan
Bayer

Completed

HCC Patient Preferences in Japan

Hepatocellular Cancer

Japan
Chugai Pharmaceutical

Completed

PD-L1 Expression in Japanese Renal Cell Carcinoma Patients

Renal Cell Carcinoma

Japan
Eli Lilly and Company

Completed

A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)

Hepatocellular Carcinoma

Japan

3

Subscribe